Kymera Therapeutics Inc. Common Stock vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 2.5× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.06% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| KYMR | ZGN | |
|---|---|---|
Market Cap | $8.87B | $3.48B |
Volume | 779,107 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $15.25 |
52-Week Low | $55.80 | $8.69 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $8.26B | $4.43B |
Dividend Yield | — | 1.06% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →